148 related articles for article (PubMed ID: 2439846)
1. Acute effects of sublingual nifedipine in patients with Raynaud's phenomenon.
Gush RJ; Taylor LJ; Jayson MI
J Cardiovasc Pharmacol; 1987 May; 9(5):628-31. PubMed ID: 2439846
[TBL] [Abstract][Full Text] [Related]
2. Nifedipine in primary Raynaud's phenomenon and in scleroderma: oral versus sublingual hemodynamic effects.
Wollersheim H; Thien T; van 't Laar A
J Clin Pharmacol; 1987 Nov; 27(11):907-13. PubMed ID: 3429697
[TBL] [Abstract][Full Text] [Related]
3. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the efficacy of the treatment of Raynaud's phenomenon with nifedipine by laser-Doppler flowmetry.
Belcaro GV; Gabini M; Cacchio M
Panminerva Med; 1987; 29(3):223-7. PubMed ID: 2962057
[No Abstract] [Full Text] [Related]
5. Nifedipine in patients with Raynaud's syndrome--effects on radial artery blood flow.
Lewis P; Psaila JV; Morgan RH; Davies WT; Woodcock JP
Eur Heart J; 1987 Nov; 8 Suppl K():83-6. PubMed ID: 3450524
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.
Coleiro B; Marshall SE; Denton CP; Howell K; Blann A; Welsh KI; Black CM
Rheumatology (Oxford); 2001 Sep; 40(9):1038-43. PubMed ID: 11561116
[TBL] [Abstract][Full Text] [Related]
7. The peripheral vascular effects of nifedipine in Raynaud's syndrome associated with scleroderma: a double blind crossover study.
Finch MB; Dawson J; Johnston GD
Clin Rheumatol; 1986 Dec; 5(4):493-8. PubMed ID: 3816096
[TBL] [Abstract][Full Text] [Related]
8. Controlled trial of nifedipine in the treatment of Raynaud's phenomenon.
Smith CD; McKendry RJ
Lancet; 1982 Dec; 2(8311):1299-301. PubMed ID: 6128596
[TBL] [Abstract][Full Text] [Related]
9. Sublingual and oral isoxsuprine in patients with Raynaud's phenomenon.
Wesseling H; den Heeten A; Wouda AA
Eur J Clin Pharmacol; 1981; 20(5):329-33. PubMed ID: 7026260
[TBL] [Abstract][Full Text] [Related]
10. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis.
Meyrick Thomas RH; Rademaker M; Grimes SM; MacKay A; Kovacs IB; Cook ED; Bowcock SM; Kirby JD
Br J Dermatol; 1987 Aug; 117(2):237-41. PubMed ID: 3307894
[TBL] [Abstract][Full Text] [Related]
11. Nifedipine-induced fingertip vasodilation in patients with Raynaud's phenomenon.
Creager MA; Pariser KM; Winston EM; Rasmussen HM; Miller KB; Coffman JD
Am Heart J; 1984 Aug; 108(2):370-3. PubMed ID: 6380254
[TBL] [Abstract][Full Text] [Related]
12. Digital and radial artery blood flow in patients with Raynaud's phenomenon in response to nifedipine.
Morgan RH; Psaila JV; Davies WT; Carolan G; Woodcock JP
Eur J Vasc Surg; 1987 Dec; 1(6):403-8. PubMed ID: 3503035
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of Raynaud's syndrome with calcium entry blockers].
Shcherbakov AB; Guseva NG; Mach ES
Ter Arkh; 1987; 59(4):89-92. PubMed ID: 3296288
[TBL] [Abstract][Full Text] [Related]
14. Nifedipine in Raynaud's phenomenon: relationship between immediate, short term and longterm effects.
Kallenberg CG; Wouda AA; Kuitert JJ; Tijssen J; Wesseling H
J Rheumatol; 1987 Apr; 14(2):284-90. PubMed ID: 3598997
[TBL] [Abstract][Full Text] [Related]
15. Responses to nifedipine by patients with Raynaud's disease and Raynaud's phenomenon secondary to another disease.
Riccio A; Del Puente A; Farinaro C; Scarpa R; Oriente P; Rocco P; Gioia M
Clin Ther; 1987; 9(2):232-7. PubMed ID: 3568066
[TBL] [Abstract][Full Text] [Related]
16. [Action of nifedipine on the post-ischemic cold hyperemia reaction in Raynaud's phenomenon].
Vayssairat M; Blaison N; Baudot N; Evenou P; Gilard M; Mathieu JF
J Mal Vasc; 1989; 14(4):299-302. PubMed ID: 2584886
[TBL] [Abstract][Full Text] [Related]
17. A double-blind cross-over study of nifedipine retard in patients with Raynaud's phenomenon.
Finch MB; Copeland S; Passmore AP; Johnston GD
Clin Rheumatol; 1988 Sep; 7(3):359-65. PubMed ID: 3067954
[TBL] [Abstract][Full Text] [Related]
18. Sympathetic activation after two weeks of nifedipine treatment in primary Raynaud's patients and controls.
Leppert J; Nilsson H; Myrdal U; Edvinsson L; Hedner T; Ringqvist I
Cardiovasc Drugs Ther; 1993 Dec; 7(6):901-7. PubMed ID: 8011569
[TBL] [Abstract][Full Text] [Related]
19. Acute effects of nifedipine on digital blood flow in human subjects with Raynaud's phenomenon: a double blind placebo controlled trial.
Wise RA; Malamet R; Wigley FM
J Rheumatol; 1987 Apr; 14(2):278-83. PubMed ID: 3298649
[TBL] [Abstract][Full Text] [Related]
20. Nifedipine as a therapeutic modality for Raynaud's phenomenon.
Winston EL; Pariser KM; Miller KB; Salem DN; Creager MA
Arthritis Rheum; 1983 Oct; 26(10):1177-80. PubMed ID: 6626276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
